Compare BioNTech SE - ADR (BNTX) vs Lululemon Athletica Inc (LULU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNTech SE - ADR vs Lululemon Athletica Inc — how do they compare? BioNTech SE - ADR trades at $91.88 (market cap $22.86B), while Lululemon Athletica Inc trades at $117.72 (market cap $13.32B). The key difference: BioNTech SE - ADR is the larger of the two by market cap, and BioNTech SE - ADR is trading nearer its 52-week high, Lululemon Athletica Inc nearer its low. Which is the better fit depends on your goals.
| BNTX | LULU | |
|---|---|---|
Market Cap | $22.86B | $13.32B |
Sector | Health | Consumer Cyclical |
52-Week High | $119.34 | $233.31 |
52-Week Low | $83.89 | $105.43 |
Enterprise Value | $6.53B | $13.94B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BioNTech (BNTX) trades at $90.07, down 1.55% today, amid a bearish technical signal and declining revenue trends. The company reported a net loss of $1.14 billion in 2025, with profitability metrics negative, though it maintains a strong cash position of $16.78 billion. Recent news highlights restructuring efforts, including site closures and a $1 billion share buyback, as it pivots focus to oncology pipeline development following reduced COVID-19 vaccine demand.
The outlook remains challenging with persistent losses and competitive pressures, but analyst consensus is bullish with a $129.67 price target. Key risks include execution of the oncology strategy and revenue volatility. The stock's current valuation reflects uncertainty, offering potential upside if pipeline milestones are met, but investors face significant operational and market headwinds.
Lululemon (LULU) trades at $120.30, up 0.87% today, showing resilience amid a challenging year. The stock has beaten earnings estimates for three consecutive quarters, with Q2 2026 results pending. Fundamentals remain strong with a 17.13% net margin and 32.03% ROE in 2025, though revenue growth is moderating. Technical indicators signal a bullish bias, with the current price near pivot point support at $121. Recent news highlights board stability after a proxy settlement but also ongoing brand controversies.
The outlook is cautiously optimistic. Valuation appears attractive with a P/E of 9.74, below sector averages, and a consensus price target of $130.53 implies upside. Key risks include North American sales weakness, intense competition, and potential brand damage from recent controversies. Earnings execution and international expansion are critical for a sustained recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →About Lululemon Athletica Inc
Lululemon Athletica Inc. designs, distributes, and markets athletic apparel, footwear, and accessories for women, men, and girls. Lululemon offers pants, shorts, tops, and jackets for both leisure and athletic activities such as yoga and running. The company also sells fitness accessories, such as bags, yoga mats, and equipment. Lululemon sells its products through more than 600 company-owned stores in 18 countries, e-commerce, outlets, and wholesale accounts. The company was founded in 1998 and is based in Vancouver, Canada.
Read more on LULU →
